---
layout: post
title: "Advanced Prostate Cancer: Developing Gonadotropin-Releasing Hormone Analogues; Guidance for Industry; Availability"
date: 2026-02-05 18:59:18 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-11410
original_published: 2022-05-27 00:00:00 +0000
significance: 8.00
---

# Advanced Prostate Cancer: Developing Gonadotropin-Releasing Hormone Analogues; Guidance for Industry; Availability

**Published:** February 05, 2026 18:59 UTC
**Source:** Federal Register
**Original Published:** May 27, 2022 00:00 UTC
**Document Number:** 2022-11410

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Advanced Prostate Cancer: Developing Gonadotropin-Releasing Hormone Analogues." This guidance describes FDA's current recommendations regarding the overall development program and clinical trial designs for developing gonadotropin-releasing hormone (GnRH) analogues to treat advanced prostate cancer. This guidance finalizes the draft guidance of the same title issued in July 2019.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/05/27/2022-11410/advanced-prostate-cancer-developing-gonadotropin-releasing-hormone-analogues-guidance-for-industry)
- API: https://www.federalregister.gov/api/v1/documents/2022-11410

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
